Gland Pharma has reported a significant 62% month-on-month increase in exports, marking a substantial improvement in the company's international business performance. This growth reflects the pharmaceutical company's strengthening position in global markets and its ability to expand its international operations effectively.

Export Performance Highlights

The company's export performance shows remarkable momentum with the reported month-on-month growth figures:

Market Implications

This substantial export growth indicates Gland Pharma's successful expansion in international pharmaceutical markets. The 62% month-on-month increase demonstrates the company's operational capabilities and market penetration strategies in global markets.

The strong export performance reflects the company's ability to meet international demand and maintain competitive positioning in the pharmaceutical sector. This growth trajectory suggests effective execution of the company's international business strategy and operational excellence in export operations.

Business Development

The significant month-on-month export increase positions Gland Pharma favorably in the competitive pharmaceutical landscape. This performance indicates the company's capacity to scale its international operations and capitalize on global market opportunities effectively.

Gland Pharma Limited has officially notified the stock exchanges about an upcoming board meeting scheduled for January 28, 2026, where directors will review and approve the company's third quarter financial performance for FY26. The pharmaceutical company submitted formal intimation letters to both BSE Limited and National Stock Exchange of India Limited regarding this regulatory requirement under SEBI guidelines.

Board Meeting Details

The board meeting agenda focuses on approving unaudited financial statements covering two distinct reporting periods. Directors will examine both standalone and consolidated financial results, providing comprehensive insights into the company's operational and subsidiary performance during the specified timeframes.

Trading Window Restrictions

Gland Pharma has implemented mandatory trading window closures in compliance with SEBI insider trading regulations. The company previously announced these restrictions to prevent any potential misuse of unpublished price-sensitive information during the financial results preparation period.

Investor Engagement Activities

The pharmaceutical manufacturer has arranged stakeholder communication sessions to discuss quarterly performance with market participants. Company management will conduct detailed presentations covering financial metrics, operational highlights, and business developments during the reporting quarter.

• Earnings Call Date: Wednesday, January 28, 2026
• Scheduled Time: 18:30 Hours (Indian Standard Time)
• Participants: Investors and Financial Analysts
• Additional Details: To be published on company website

Regulatory Communication

Company Secretary and Compliance Officer Sampath Kumar Pallerlamudi signed the official communication sent to stock exchanges. The formal notification ensures compliance with Regulation 29 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, maintaining transparency standards for listed pharmaceutical companies.

Gland Pharma operates from its registered office in Hyderabad's Medchal-Malkajgiri District, with corporate headquarters located in Sangareddy District. The company maintains active communication channels through its official website at www.glandpharma.com , where stakeholders can access updated information about earnings calls and financial announcements.